重组人生长激素对特发性矮小症儿童血清IGF-1/IGFBP-3摩尔比的影响及其临床意义-东南大学学报医学版

重组人生长激素对特发性矮小症儿童血清IGF-1/IGFBP-3摩尔比的影响及其临床意义

单位：中国人民解放军空军军医大学第一附属医院儿科, 陕西西安 710032

关键词：重组人生长激素特发性矮小症胰岛素样生长因子-1/胰岛素样生长因子结合蛋白-3摩尔比身高标准差分值

分类号：R725

出版年·卷·期（页码）：2023·42·第五期（681-687）

摘要：

目的:探讨重组人生长激素(rhGH)对特发性矮小症(ISS)儿童血清胰岛素样生长因子-1(IGF-1)/IGF结合蛋白-3(IGFBP-3)摩尔比的影响及临床意义。方法:收集我院2016年6月至2020年6月收治的132例学龄期ISS儿童的临床和实验室记录进行回顾性分析,所有儿童接受至少2年的rhGH治疗。采用化学发光法测定血清IGF-1和IGFBP-3浓度,并计算摩尔比。rhGH治疗前后数据差值(Δ)=治疗后值-治疗前值。rhGH治疗1年后Δ身高标准差分值(SDS)<0.3定义为治疗反应不良,Δ身高SDS ≥ 0.3定义为治疗反应良好。结果:与基线相比,rhGH治疗1年和2年身高SDS、IGF-1 SDS、IGFBP-3 SDS以及IGF-1/IGFBP-3摩尔比SDS均增加(P<0.05)。rhGH治疗反应不良的学龄期ISS儿童基线时的实际年龄、骨龄明显高于反应良好儿童,同时IGF-1/IGFBP-3摩尔比和IGF-1/IGFBP-3摩尔比 SDS明显低于反应良好儿童(P<0.05)。经多因素Logistic回归分析,基线时IGF-1/IGFBP-3摩尔比SDS较低是rhGH治疗反应不良的独立危险因素(P<0.001)。rhGH治疗1年或2年后的Δ身高 SDS与ΔIGF-1/IGFBP-3摩尔比、ΔIGF-1/IGFBP-3摩尔比 SDS呈正相关(P<0.05)。进一步校正作为协变量的基线身高后,治疗2年后Δ身高SDS与ΔIGF-1/IGFBP-3摩尔比SDS呈正相关(P<0.05)。结论:血清IGF-1/IGFBP-3摩尔比SDS与rhGH治疗后身高增加反应相关,可能适合作为预测学龄期ISS儿童接受rhGH治疗后身高反应的生物标志物。

Objective: To investigate the effect and clinical significance of recombinant human growth hormone(rhGH) on serum insulin-like growth factor-1(IGF-I)/IGF-binding protein-3(IGFBP-3) molar ratio in children with idiopathic short stature(ISS). Methods: From June 2016 to June 2020, the clinical and laboratory records of 132 school-age ISS children admitted to our hospital were collected for retrospective analysis. All children had received rhGH treatment for at least 2 years. Serum IGF-1 and IGFBP-3 concentrations were measured by chemiluminescence method, and the molar ratio was calculated. rhGH data difference before and after treatment(Δ)=Data value after treatment-data value before treatment. After 1 year of rhGH treatment, poor response was defined as Δheight standard deviation score(SDS) <0.3, and good response was defined as Δheight SDS ≥ 0.3. Results: Compared with baseline, the height SDS, IGF-1 SDS, IGFBP-3 SDS and IGF-1/IGFBP-3 molar ratio SDS increased after 1 and 2 years of rhGH treatment(P<0.05). The actual age and bone age of school-age ISS children with poor response to rhGH treatment at baseline were significantly higher than those with good response, and IGF-1/IGFBP-3 molar ratio and IGF-1/IGFBP-3 molar ratio SDS were significantly lower than those with good response(P<0.05). Multivariate Logistic regression analysis showed that lower IGF-1/IGFBP-3 molar ratio SDS at baseline was an independent risk factor for poor response to rhGH treatment(P<0.001). After 1 year or 2 years of rhGH treatment, ΔHeight SDS was positively correlated with ΔIGF-1/IGFBP-3 molar ratio and ΔIGF-1/IGFBP-3 molar ratio SDS(P<0.05). After further adjusting baseline height as a covariable, ΔHeight SDS was significantly positively correlated with ΔIGF-1/IGFBP-3 molar ratio SDS after 2 years of treatment(P<0.05). Conclusion: Serum IGF-1/IGFBP-3 molar ratio SDS is related to the height increase response after rhGH treatment, and may be suitable as a biomarker to predict the height response of school-age ISS children after rhGH treatment.

参考文献：

[1] 李慧杰.健脾肾助长方辅助重组人生长激素治疗小儿特发性矮小症的效果观察[J].中国中医药科技,2022,29(2):247-248.
[2] 吴睿峰,庄承.肝脾补益法联合rhGH治疗ISS骨骼增长量的长期随访研究[J].重庆医学,2022,51(15):2605-2608.
[3] 郭艳艳,蒋成霞,姚兰,等.不同剂量重组人生长激素治疗对特发性矮小症患儿身高、体重以及血清IGF-1和IGFBP-3表达的影响[J].解放军医药杂志,2020,32(3):44-47.
[4] PALTOGLOU G,DIMITROPOULOS I,KOURLABA G,et al.The effect of treatment with recombinant human growth hormone(rhGH) on linear growth and adult height in children with idiopathic short stature(ISS):a systematic review and meta-analysis[J].J Pediatr Endocrinol Metab,2020,33(12):1577-1588.
[5] 胡玲,黎小年.重组人生长激素对特发性矮小症患儿血清Ghrelin及胰岛素样生长因子-1水平的影响[J].中国现代医学杂志,2019,29(15):108-111.
[6] 舒静娜,祁建凤.重组人生长激素对特发性矮小症患儿胰岛素样生长因子-1、胰岛素样生长因子结合蛋白-3的影响[J].中国妇幼保健,2020,35(3):486-488.
[7] KIM M,KIM E Y,KIM E Y,et al.Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy:LG growth study database[J].PLoS One,2021,16(11):e0259287.
[8] JOHANNSSON G,BIDLINGMAIER M,BILLER B M K,et al.Growth Hormone Research Society perspective on biomarkers of GH action in children and adults[J].Endocr Connect,2018,7(3):R126-R134.
[9] BALLERINI M G,BRASLAVSKY D,SCAGLIA P A,et al.Circulating IGF-I,IGFBP-3 and the IGF-I/IGFBP-3 molar ratio concentration and height outcome in prepubertal short children on rhGH treatment over two years of therapy[J].Horm Res Paediatr,2017,88(5):354-363.
[10] 江载芳,申昆玲,沈颖.诸福棠实用儿科学[M].8版.北京:人民卫生出版社,2015:102-105.
[11] 张一民.切实提高学生体质健康水平——《国家学生体质健康标准(2014年修订)》解读[J].体育教学,2014,34(9):5-11.
[12] BAYLEY N,PINNEAU S R.Tables for predicting adult height from skeletal age:revised for use with the Greulich-Pyle hand standards[J].J Pediatr,1952,40(4):423-441.
[13] PEREZ-COLON S,LAZAREVA O,PURUSHOTHAMAN R,et al.Baseline IGFBP-3 as the key element to predict growth response to growth hormone and IGF-1 therapy in subjects with non-GH deficient short stature and IGF-1 deficiency[J].Int J Endocrinol Metab,2018,16(3):e58928.
[14] SAVAGE M O,STORR H L,BACKELJAUW P F.The continuum between GH deficiency and GH insensitivity in children[J].Rev Endocr Metab Disord,2021,22(1):91-99.
[15] POLIDORI N,CASTORANI V,MOHN A,et al.Deciphering short stature in children[J].Ann Pediatr Endocrinol Metab,2020,25(2):69-79.
[16] GUTEFELDT K,HEDMAN C A,THYBERG I S M,et al.Dysregulated growth hormone-insulin-like growth factor-1 axis in adult type 1 diabetes with long duration[J].Clin Endocrinol(Oxf),2018,89(4):424-430.
[17] WITKOWSKA-SDEK E,KUCHARSKA A M,RUMISKA M,et al.Decreased thyroxine levels during rhGH Therapy in children with growth hormone deficiency[J].J Clin Med,2021,10(21):5100-5107.
[18] MEINHARDT U J,HO K K.Modulation of growth hormone action by sex steroids[J].Clin Endocrinol(Oxf),2006,65(4):413-422.
[19] HAN W,ZHANG J,SONG T,et al.Significance of recombinant human growth hormone therapy in promoting growth and development of children with idiopathic short stature[J].Pak J Med Sci,2022,38(7):2016-2020.
[20] CIANFARANI S.Risk of cancer in patients treated with recombinant human growth hormone in childhood[J].Ann Pediatr Endocrinol Metab,2019,24(2):92-98.
[21] LU T,FORGETTA V,WU H,et al.A polygenic risk score to predict future adult short stature among children[J].J ClinEndocrinol Metab,2021,106(7):1918-1928.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录